Dose intensity of cytarabine, daunorubicin, and etoposide in selected acute myeloid leukemia (AML) trials.
| . | . | . | . | Cumulative Dose (mg/m2) . | ||||
|---|---|---|---|---|---|---|---|---|
| Study . | Number of Patients . | Number of Cycles . | Estimated Time to Assess Remission (weeks) . | Cytarabine . | Daunorubicin . | Etoposide . | CR Rate (%) . | Overall Survival Rate . |
| Some patients received idarubicin (12 mg of idarubicin = 60 mg of daunorubicin) and mitoxantrone (10 mg of mitoxantrone = 40 mg of daunorubicin). | ||||||||
| Abbreviations: POG, Pediatric Oncology Group; AML-91, acute myeloid leukemia-91 study (St. Jude Children’s Research Hospital); MRC-10/12, Medical Research Council-10/12 study; BFM-93 and Oncology-93 study; ANZCCSG-AML2, Australian and New Zealand Children’s Cancer Study Group AML-2 study; BFM, Berlin-Frankfurt-Munster-93 study; LAME89/91, Leucamie Aique Myeloide Enfant-89/90 study; NOPHO, Nordic Society for Paediatric Haematology | ||||||||
| POG 882124 | 649 | 2 | 6–8 | 18,700 | 135 | — | 85 | 3-yr, 42% |
| CCG-289125 (intensive timing) | 295 | 4 | 16–17 | 3200 | 320 | 1600 | 75 | 3-yr, 51% |
| AML-9126 | 73 | 3–4 | 8–12 | 1250–3750 | 90–270 | 400–1200 | 78 | 5-yr, 53% |
| MRC-1021 | 341 | 2 | 8–10 | 1800 | 300 | 0–1000 | 83 | 7-yr, 56% |
| MRC-129 | 564 | 2 | 8–10 | 1800 | 288–300* | 1000 | 92 | 5-yr, 68% |
| BFM-9322 | 471 | 4 | 16–22 | 21,200–39,200 | 264–380* | 950 | 82 | 5-yr, 60% |
| LAME-89/9123 | 268 | 2 | 6–8 | 1400–2000 | 225–315* | — | 90 | 6-yr, 60% |
| NOPHO-9317 | 219 | 2–322 | 8–6 | 1600–13,300 | 150–195* | 800–900 | 91 | 7-yr, 64% |
| ANZCCSG20 (AML–2) | 167 | 2 | 8–0 | 12,700–18,700 | 150 | — | 91 | 5-yr, 55% |
| . | . | . | . | Cumulative Dose (mg/m2) . | ||||
|---|---|---|---|---|---|---|---|---|
| Study . | Number of Patients . | Number of Cycles . | Estimated Time to Assess Remission (weeks) . | Cytarabine . | Daunorubicin . | Etoposide . | CR Rate (%) . | Overall Survival Rate . |
| Some patients received idarubicin (12 mg of idarubicin = 60 mg of daunorubicin) and mitoxantrone (10 mg of mitoxantrone = 40 mg of daunorubicin). | ||||||||
| Abbreviations: POG, Pediatric Oncology Group; AML-91, acute myeloid leukemia-91 study (St. Jude Children’s Research Hospital); MRC-10/12, Medical Research Council-10/12 study; BFM-93 and Oncology-93 study; ANZCCSG-AML2, Australian and New Zealand Children’s Cancer Study Group AML-2 study; BFM, Berlin-Frankfurt-Munster-93 study; LAME89/91, Leucamie Aique Myeloide Enfant-89/90 study; NOPHO, Nordic Society for Paediatric Haematology | ||||||||
| POG 882124 | 649 | 2 | 6–8 | 18,700 | 135 | — | 85 | 3-yr, 42% |
| CCG-289125 (intensive timing) | 295 | 4 | 16–17 | 3200 | 320 | 1600 | 75 | 3-yr, 51% |
| AML-9126 | 73 | 3–4 | 8–12 | 1250–3750 | 90–270 | 400–1200 | 78 | 5-yr, 53% |
| MRC-1021 | 341 | 2 | 8–10 | 1800 | 300 | 0–1000 | 83 | 7-yr, 56% |
| MRC-129 | 564 | 2 | 8–10 | 1800 | 288–300* | 1000 | 92 | 5-yr, 68% |
| BFM-9322 | 471 | 4 | 16–22 | 21,200–39,200 | 264–380* | 950 | 82 | 5-yr, 60% |
| LAME-89/9123 | 268 | 2 | 6–8 | 1400–2000 | 225–315* | — | 90 | 6-yr, 60% |
| NOPHO-9317 | 219 | 2–322 | 8–6 | 1600–13,300 | 150–195* | 800–900 | 91 | 7-yr, 64% |
| ANZCCSG20 (AML–2) | 167 | 2 | 8–0 | 12,700–18,700 | 150 | — | 91 | 5-yr, 55% |